---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-25-000021"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2025-01-29T23:59:59+00:00"
generated_at: "2026-05-27T07:03:28.614175+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Praxis reports $470M cash, NDA plans for ulixacaltamide in 2025, and UCB option exercise for KCNT1

## Summary
- Cash, cash equivalents and marketable securities ~$470M at Dec 31, 2024; runway into 2028.
- Interim analysis of Essential3 Study 1 for ulixacaltamide in essential tremor expected Q1 2025; NDA filing planned for 2025.
- UCB exercised option to license KCNT1 small molecule; Praxis eligible for up to ~$100M milestones plus tiered royalties.
- RADIANT (vormatrigine) topline in H1 2025; POWER1 (vormatrigine) topline by year-end 2025.
- EMBOLD cohort 2 for relutrigine on track with NDA filing expected in 2026; third RPDD received for Dravet Syndrome.

## SEC filing metadata
- accession: 0001689548-25-000021
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2025-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/0001689548-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/prax-20250112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-25-000021
- JSON: https://secwatch.observer/filing/0001689548-25-000021.json
- Plain text: https://secwatch.observer/filing/0001689548-25-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.